Article title: Plasma brain-derived tau: analytical and clinical validation of the first commercial immunoassay

Authors: Michel N. Nafash[1,2,3], Sarah E. Svirsky[4], Xuemei Zeng[1,2,3], Yijun Chen[1,2,3,5], Julia K. Kofler[3,6], Ann D. Cohen[1,3], David O. Okonkwo[4], Oscar L. Lopez[3,7], Ava M. Puccio[4#], Thomas K. Karikari[1,2,3*#]

[1]Department of Psychiatry, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA

[2]Biofluid Biomarker Laboratory, Western Psychiatric Hospital, University of Pittsburgh Medical Center, Pittsburgh PA, USA

[3]Alzheimer's Disease Research Center, University of Pittsburgh, Pittsburgh PA, USA

[4]Department of Neurological Surgery, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA

[5]Department of Chemistry, University of Pittsburgh, Pittsburgh, PA, USA

[6]Department of Pathology, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA

[7]Department of Neurology, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA

[#]Joint senior authors

*Corresponding authors

Corresponding Author:

Thomas K. Karikari

UPMC Western Psychiatric Hospital

3811 O'Hara St.

Pittsburgh, PA 15213

Email: karikaritk@upmc.edu

Phone: +1 412 246 5395

Keywords: Brain-derived tau, Traumatic brain injury, Alzheimer's disease, Analytical validation, Clinical validation, Blood-based biomarkers

Abstract

Background: Brain-derived tau (BD-tau) is a promising blood-based biomarker for neurodegeneration/brain injury in neurodegenerative and acute neurological disorders. However, widespread use is hampered by lack of commercial assays.

Methods: Using the Simoa® HD-X analyzer, we evaluated the first commercial research-use only BD-tau Advantage PLUS assay's robustness, precision, dilution linearity, spike recovery, specificity, and limits of detection. Matrix effect was examined by comparing BD-tau levels in n=48 plasma/serum and n=20 plasma/CSF sample pairs. Clinical performance was examined in a traumatic brain injury (TBI) cohort.

Results: Twenty repeated measurements of three plasma samples gave intra- and inter-plate CVs ≤7.24%. A median drift of 8.00% (decrease) was observed from the start to the end of a full plate run. Analytically, BD-tau concentrations decreased linearly up to 16-fold dilution, spike recovery was 86-96%, and signals were highly specific to the CNS-abundant tau441 but not the peripherally-enriched "big-tau" isoform. Moreover, signals were stable for up to four freeze/thaw cycles. Furthermore, significant correlations were observed in the plasma/serum (r=0.8392; p<0.0001) and plasma/CSF (r=0.6150; p=0.0039) pairs. Finally, plasma BD-tau was elevated in severe-acute TBI vs. chronic-mixed TBI and unaffected controls (p<0.0001; AUC=0.9986, and p<0.0001; AUC=1.000, respectively). In severe-acute TBI patients, plasma BD-tau was correlated with plasma p-tau217 (r=0.5761, p=0.0005), NfL (r=0.8910, p=0.0001), and GFAP (r=0.5424, p=0.0011). CSF BD-tau and CSF p-tau217 were strongly correlated (r=0.9667, p=0.0002).

Conclusion: BD-tau Advantage PLUS produces robust brain-derived tau-specific readings that demonstrate utility in detecting severe-acute TBI.

Introduction

Clinical care for neurological disorders is experiencing a shift towards the integration of biomarkers into standard practices for diagnosis, tracking disease progression, and measuring response to therapies [1]. A biomarker can be objectively quantified and, when thoroughly validated, can act as a surrogate indicator of disease state and stage, as well as target engagement and efficacy in therapeutic campaigns [1,2]. For example, in several neurodegenerative diseases, cerebrospinal fluid (CSF) biomarkers have been incorporated into clinical practice for over a decade in conditions like Alzheimer's disease (AD) and Parkinson disease (PD) [3–8]. However, the utility of CSF biomarkers is limited by accessibility, invasiveness, and cost concerns [9,10]. Blood-based biomarkers have seen a fast emergence due to the ease of collection, affordability, and comparable performance to CSF biomarkers [4,8,9,11,12].

A main limitation of blood-based biomarker assays for neurological disorders is the potential contamination of blood measurements by protein forms in systemic circulation originating from peripheral sources and not released from the central nervous system (CNS) [6,13–16]. This issue affects the reliability of several prominent biomarkers when measured in plasma including amyloid-beta (Aß) peptides, given their high levels in both CNS and non-CNS sources such as platelets and the liver which compromises the fold change in plasma when compared with levels in CSF [13]. A similar situation exists for tau protein which in addition to being abundant in the CNS, is equally found in many non-CNS tissues including lungs, heart, kidneys, muscles, and the peripheral nervous system [6,14–16]. This accounts, at least partly, for why the neurodegeneration/brain injury biomarker total tau performs poorly in blood despite its high accuracies in CSF, which show no correlations to blood-based measurements in AD

72 [6,17]. Therefore, optimization of blood-based biomarker assays to improve their selectivity for
73 CNS-originating proteins is needed to improve their accuracies and alignment with their CSF
74 biomarker assay counterparts while maintaining the integrity of their measurements.

75 In 2023, a blood-based assay referred to as brain-derived tau (BD-tau), which provides a
76 "barcoding" approach to select for tau protein released from the CNS, was reported [6]. The
77 main unique feature is that BD-tau uses a novel antibody combination that ensures signal
78 specificity to analytes only containing the six tau isoforms abundantly found in the adult human
79 brain vs. the higher molecular weight tau isoforms (containing the exon 4a insert) more
80 commonly released from the periphery (thus the name big-tau) [6]. Plasma/serum BD-tau levels
81 strongly correlated with CSF BD-tau and CSF total tau, outperforming blood-based total-tau in
82 this regard [6,18]. Moreover, plasma and serum BD-tau levels are strongly correlated [18].

83 In addition to showing strong correlations with other plasma and CSF biomarkers of AD
84 as well as with baseline and worsening cognitive decline, BD-tau levels were more related to
85 neurodegeneration in AD vs. non-AD neurodegenerative diseases, and appeared unaffected by
86 common comorbidities (e.g., diabetes) and *APOE ε4* carriership [6,19,20]. In addition,
87 plasma/serum BD-tau levels agree strongly with the severity of neurodegeneration/brain injury
88 have demonstrated clinical utility for rapidly progressive AD and Creutzfeldt-Jakob disease [21].
89 In severe traumatic brain injury (sTBI), initial BD-tau measurements at the time of and one week
90 after injury were more robustly correlated with worse clinical outcome scores than plasma total-
91 tau, p-tau231, NfL, showing the significance of CNS selective-tau in outcome prediction [22].
92 Finally, BD-tau shows a more coherent time-dependent pattern to predict outcome of traumatic
93 brain injury than both NfL and total-tau [22].

94 To date, BD-tau studies have been limited to using the original prototype assay. More
95 recently, a commercial version of the blood-based BD-tau measurement assay, the Quanterix®
96 BD-tau Advantage PLUS reagent kit, became available. However, independent analytical and

97 clinical validation is lacking. In this study, we performed analytical validation tests according to
98 the FDA's recommendations for bioanalytical method validation [23], as well as analytical
99 chemistry experts, on the aforementioned assay to ensure the accuracy and reliability of
100 measurements [24]. We also report validation of the assay in clinical severe TBI patients.

101 **Materials and Methods**

102 Study Cohorts and Sample Collection

103 Plasma samples used for validation experiments were collected from participants at the
104 University of Pittsburgh's Alzheimer's Disease Research Center (ADRC) into
105 ethylenediaminetetraacetic acid (EDTA) tubes. Samples were spun at 2000xg for 10 minutes at
106 4°C to separate plasma from whole blood, then aliquoted into microtubes and stored at -80°C
107 until time of use. Storage conditions for samples collected purposefully for assay stability
108 experiments differed from this protocol as highlighted in Supplemental Table 1. Additionally, a
109 pooled plasma sample commercially acquired from Precision for Medicine Bethesda, MD, USA
110 was aliquoted into 500µL single-use aliquots and stored at -80°C until needed. Plasma and
111 serum pairs were collected from the ADRC cohort following procedures described previously
112 [25] and stored at -80°C pending use. Biobanking measures followed standard guidelines [26].

113 Severe TBI participants were prospectively enrolled at admission between 2019-2024
114 through the Brain-Trauma Research Center at the University of Pittsburgh, Pittsburgh, PA, USA.
115 Eligibility was determined by the presence of severe TBI defined as Glasgow Coma Scale
116 (GCS) score <9 at enrollment and age 16–80 years. Exclusion criteria were penetrating brain
117 injury, brain death and pregnancy.

118 Chronic mixed TBI and control individuals were recruited through a Peer Reviewed
119 Alzheimer's Research Program (PRARP) study. Inclusion criteria for the chronic mixed TBI
120 group were: 1. History of at least one TBI that occurred over one year prior to enrollment; 2. Age

121 29-59 years; 3. Suspected cognitive impairment (based on neuropsychological assessment or
122 professional diagnosis of cognitive impairment). Exclusion criteria for the chronic mixed TBI
123 group were: 1. History of penetrating TBI, 2. history of pre-existing neurologic or
124 neurodegenerative disorder, 3. History of psychiatric disorder, 4. Active drug or alcohol
125 dependence, 5. Contraindication to magnetic resonance imaging or PET scans. Inclusion
126 criteria for the control group were age 29-59 years and a score less than 1 the Ascertain
127 Demential 8 item Questionnaire (AD8), and exclusion criteria were a history of blast exposure or
128 moderate to severe TBI.

129 Blood was taken from an indwelling catheter placed as a routine standard of care using
130 6 mL K3EDTA tubes (Greiner Bio-One, Fischer Scientific). To isolate plasma, samples were
131 spun for 15 mins at 1500xg within 60 minutes of collection and aliquoted into cryovials for
132 storage at -80 °C. For the severe TBI group plasma collected on day 4 post-injury was used in
133 this study. For the chronic mixed TBI and control groups, baseline plasma was collected at time
134 of consent, using similar methods.

135 A subset of the chronic mixed TBI (n=7) and control subjects (n=7) had CSF collected by
136 lumbar puncture. CSF was collected from sTBI participants (n=9) using an indwelling
137 ventriculostomy catheter via external ventricular drainage. All samples were gently inverted to
138 avoid possible gradient effects, briefly centrifuged at low speed, and aliquoted into
139 polypropylene cryovials prior to freezing and storage at –80°C.

140 The Pittsburgh ADRC and the Brain-Trauma and PRARP TBI studies were reviewed and
141 approved by the Institutional Review Board at the University of Pittsburgh. The reference
142 numbers for approvals are as follows: ADRC study, MOD19110245-023; BTRC study,
143 19030228; Military CTE study, 19110161.

144 <u>Data Collection</u>

145 Data for this study were collected and analyzed at the University of Pittsburgh's Biofluid
146 Biomarker Laboratory between June 2024 and March 2025. Biomarker tests were run on
147 Quanterix® Simoa® HD-X analyzer using the Quanterix® BD-tau Adv PLUS reagent kit (Lots
148 504274 and 504275). All average enzymes per bead (AEB) and replicate concentration values
149 were acquired directly from instrument-generated exports, except for concentrations calculated
150 with the custom-generated universal calibration curve. Calibrators were run in either duplicates
151 or triplicates. We excluded calibrator H (60.0 pg/mL) after determining its non-importance for
152 estimating BD-tau concentrations in plasma and serum based on interpolating concentrations
153 with calibration curves using different subsets of calibrators.

154 Experiment Procedures

155 Analytical validation experimental procedures are described in Supplemental Appendix
156 1.1.

157 Statistical Analyses

158 All statistical analyses were performed in GraphPad Prism (v10.1.2(324)) and Microsoft
159 Excel (V2503 Build 16.0.18623.20266). Descriptive statistics, Spearman correlations, Friedman
160 and Dunn's multiple comparisons tests, and Kruskal-Wallis one-way ANOVA and multiple
161 comparison tests were conducted using GraphPad. Since data were not normally distributed,
162 non-parametric tests were used and the results presented as median (IQR) values. Prism was
163 also used for simple linear and 4-parameter logistic (4-PL) regression models, the latter being
164 used to generate the universal calibration curve. Microsoft Excel was used to organize the
165 preparation and results of tests such as dilution linearity and spike recovery, for normalization of
166 the precision and sample stability tests, and to apply the 4-PL model to generate assay
167 concentrations. For the lower limit of quantification (LLOQ) calculations, 4-PL parameters
168 generated by the instrument were used, whereas the universal calibration curve parameters

169 were acquired from GraphPad Prism's interpolation of the calibrator AEB data. Finally, QC
170 performance and calculation of the coefficients of variation (CV) were also done using MS
171 Excel.

172 **Results**

173 Cohort characteristics

174 Characteristics of the participants (n=50) who provided the plasma/serum pairs have
175 been described previously [25]. Characteristics of the participants (n=63) of the pilot TBI cohort
176 are found in Supplemental Table 2.

177 Assay details

178 We used an eight-point calibration curve for the BD-tau assay, with seven non-blank
179 calibrators ranging from 0.246 pg/mL to 150 pg/mL. See Supplemental Figure 1 for a sample
180 calibration curve.

181 Robustness and Precision

182 We assessed the robustness, repeatability, and intermediate precision of the assay
183 under two different conditions. First, three QC samples with different BD-tau levels were used to
184 evaluate assay reproducibility. For samples analyzed on the same plate (n=10 independent
185 runs), the median CV for the high QC sample [median: 223 pg/mL (IQR: 207-227)] was 5.65%,
186 versus 5.23% and 7.03% for the medium and low QC samples [16.4 pg/mL (15.2-16.7)] and
187 [7.42 pg/mL (7.07-7.59), respectively]. These %CVs were within the widely accepted range of
188 <20% [24]. Furthermore, the median drift in signal from the start to the end of the same plate for
189 aliquots of identical QC samples was ~8.00% (range: 7.40-13.9%) [Figure 1A]. Overall assay
190 robustness was good with a %CV of up to ~7.24% for the pooled between-plate data [Figure

191 1B]. These results suggest that the assay is robust for independent measurements performed at
192 different times.

193 The second condition involved five different plasma samples that were measured 25
194 individual times, across five runs over five different days. For each sample evaluated, Figure 1C
195 shows the % plasma BD-tau levels normalized to the mean of all 25 measurements, used to
196 quantify repeatability and intermediate precision. The repeatability (CV_r) was 6.47%-12.4% and
197 the intermediate precision (CV_{Rw}) 9.52%-15.1% [Supplemental Table 3]. The measured
198 endogenous concentrations of each sample are shown in Figure 1D and Supplemental Table 2.
199 This set of results indicates that the assay is robust, and that results can be compared to one
200 another within the same batch/lot.

201 Limits of Quantification

202 AEB signals for 16 blank samples ranged between 4.290×10^{-3} and 8.740×10^{-3}
203 [Supplemental Table 4], with the mean and SD being 5.990×10^{-3} and 1.070×10^{-3}, respectively.
204 The LLOQ signal (mean + 10 standard deviations) becomes 0.0167, which gives an analytical
205 LLOQ of 0.0933 pg/mL when calculated according to Equation 1 [Supplemental Appendix 1.1.3].
206 The manufacturer's analytical LLOQ is slightly higher at 0.133 pg/mL [27]. After adjusting for the
207 4X on-board dilution recommended for plasma samples, the functional LLOQ becomes 0.373
208 pg/mL.

209 For the ULOQ determination, the median concentration of the sample with the highest
210 signals being 460 pg/mL, which gives a functional concentration of 1840 pg/mL after adjusting
211 for the 4X on-board dilution. However, the highest point in the dynamic range of the assay
212 calibration curve is 150 pg/mL (600 pg/mL dilution adjusted concentration) and marks the end of
213 the dynamic range as published by the manufacturer [27]. Thus, 600 pg/mL is the highest point
214 that can be reliably produced by the assay's calibration curve.

215 Signal specificity

216 We compared BD-tau results for equimolar concentrations of the recombinant CNS-
217 abundant full-length tau441 (2N4R) isoform vs. the much longer big tau isoform commonly
218 expressed in peripheral tissue in both calibrator diluent (manufacturer recommended) and four-
219 fold diluted low-concentration QC plasma to account for potential matrix effects. Across three
220 concentrations tested within the dynamic range of the assay (25 pg/ml, 50 pg/mL, and 100
221 pg/mL), signals for the 2N4R tau441 isoform increased proportionally to the dilution fold when
222 diluted in either diluent or QC plasma. However, the big tau isoform signals remained similar to
223 the blank values [Figure 2, Supplemental Table 5]. This indicates that the assay is highly specific
224 for CNS-abundant tau isoforms.

225 Dilution Linearity

226 Dilution linearity data of three plasma samples were obtained from serial four-fold
227 dilutions up to 4096-fold [Figure 3A]. Compared with the undiluted stock, the observed
228 concentrations for all samples at the 4- and 16-fold dilutions were as expected, with measured
229 values decreasing proportionally. The mean dilution-adjusted relative error was 112% for 4-fold
230 dilution and 120% for 16-fold dilution [Figure 3B]. For the non-diluted, and 4- and 16-fold
231 dilutions, the R^2 was 0.908, 0.903, and 0.906 for plasma samples 1, 2, and 3, respectively.
232 However, after the 64X dilution the samples stopped responding to dilutions. The dilution-
233 adjusted relative results error showed that beyond 16-fold dilution, the error becomes extremely
234 high and can potentially lead to falsely high concentrations of plasma BD-tau. Together, the
235 results show that the BD-tau assay concentrations change linearly with the degree of dilution up
236 to 16-fold depending on the starting concentration.

237 Spike Recovery

238 Spike recovery results were obtained from two different four-fold diluted plasma samples
239 with non-spiked neat concentrations of 1.19 pg/mL and 1.67 pg/mL for Sample 1 and Sample 2,
240 respectively. For both samples, recovery was within the 80-120% acceptable range for all
241 chosen spike concentrations [Figure 4 and Supplemental Table 6].

242 Plasma/Serum Comparison

243 Of the n=50 plasma/serum pairs compared, 48 pairs gave values that were eligible for
244 analysis, as two returned technical errors. Although BD-tau levels were higher in serum vs. in
245 plasma [Figure 5A], there was a significant positive correlation (Spearman's rho = 0.8392,
246 $p<0.0001$) between the levels in the paired samples [Figure 5B].

247 Sample Stability

248 Stability of three independent plasma samples was tested after storage in different
249 temperature conditions and repeated freeze/thaw (f/t) cycles. Normalized concentrations
250 showed that the storage conditions before moving the sample to -80°C had no impact
251 [Supplemental Figure 2]. Concerning the impact of f/t cycles, increasing the number of f/t cycles
252 tended to increase the levels of plasma BD-tau. Friedman test revealed significant differences in
253 sample concentrations between the freeze thaw cycles ($p=0.0004$), with Dunn's multiple
254 comparisons test showing significant differences from the reference sample at f/t cycles number
255 6 ($p=0.0101$) and 8 ($p=0.0011$) [Supplemental Figure 3]. These findings show that plasma
256 samples for BD-tau measurement should not be exposed to more than four f/t cycles.

257 Clinical validation in TBI

258 In the pilot TBI cohort that included n=64 participants with plasma samples, including 34
259 sTBI participants whose plasma was collected at day 4 post injury, with a subset of 20
260 additionally having CSF samples [Supplemental Table 2], participants were grouped as
261 unaffected controls, chronic-mixed TBI (cmTBI), and severe-acute TBI (sTBI). Nonparametric

262 Kruskal-Wallis one-way ANOVA tests indicated significant differences among the three groups in
263 both CSF (p=0.0168) and plasma (p<0.0001) BD-tau. Subsequent multiple comparisons test
264 showed that The Kolmogorov-Smirnov test showed that CSF BD-tau distinguished between
265 sTBI and other groups (sTBI vs cmTBI, p<0.0001; sTBI vs control, p<0.0001), but not between
266 cmTBI and controls [Figure 6A]. On the other hand, multiple comparisons tests in CSF did not
267 reveal any significant differences between controls and either sTBI or cmTBI. However, a
268 significant difference exists between sTBI and cmTBI (p=0.0286) [Figure 6B]. Overall, the
269 median BD-tau readings in CSF/plasma pairs were 378 pg/mL and 9.23 pg/mL in CSF and
270 plasma, respectively, suggesting that ~2.47% (1.62-3.35) of the BD-tau values in CSF are
271 reflected in plasma for the same individual.

272 Additionally, in TBI groups, there was an inverse significant correlation between plasma BD-tau
273 levels and Glasgow Outcome Scale – Extended (GOS-E) scores (spearman rho = -0.6727,
274 p<0.0001), showing that higher BD-tau levels correspond with worse outcomes. In addition,
275 there was a significant difference in the GOS-E score between those with sTBI and those with
276 cmTBI [Supplemental Figure 4]. Moreover, when looking at the cohort, a significant positive
277 correlation was seen between plasma and CSF BD-tau readings (r=0.6150, p=0.0039).

278 Supplemental Table 7 summarizes plasma/CSF BD-tau correlations with p-tau217, NfL,
279 and GFAP, showing strong significant positive correlations in both matrices. In the sTBI group,
280 BD-tau displayed a significant correlation with p-tau217 in both plasma (p=0.0005) and CSF
281 (p=0.0002), but with the CSF correlation being understandably stronger than that of plasma
282 (r=0.9667 and 0.5761, respectively). Similar BD-tau-p-tau217 correlations existed in the control
283 and cmTBI groups. Plasma BD-tau was correlated with plasma NfL (r=0.8910, p<0.0001) and
284 GFAP (r=0.5424, p=0.0011) in the sTBI group, whereas correlations in the cmTBI and control
285 groups did not reach significance.

286 **Discussion**

287 We have presented an independent validation of the first commercially available BD-tau
288 assay recently released by the biotech company Quanterix®. BD-tau is a novel blood biomarker
289 to detect neurodegeneration/brain injury, with promising results published for different
290 neurological conditions including AD, TBI [6,18,19,21] and stroke [28]. However, previous
291 studies have used in-house research use only (RUO) assays, with no commercially available
292 methods to provide widespread standardized access to this biomarker. In the current study, we
293 evaluated the assay's robustness and precision, spike recovery, dilution linearity, and sample
294 stability. We also assessed the lot-to-lot comparisons, and correlations in different matrices than
295 plasma including serum and CSF. Finally, we showed the utility of BD-tau in a clinical TBI
296 cohort. These findings show that the BD-tau assay fulfills key analytical parameters
297 recommended by regulatory agencies and neurochemistry expert groups.

298 The high robustness and precision (based on CVs significantly lower than 20%) show
299 that the assay test-retest variations are within limits allowable in clinical laboratories within and
300 between runs [24].

301 Our results show that plasma samples with high concentrations can be diluted up to 16-
302 fold (combination of on-board and bench dilutions) and still give reliable concentrations within
303 the linear range of the calibration curve, with reproducible readings. Further dilution is not
304 recommended as it may lead to inaccurate signals. Moreover, assay recovery was high; the
305 concentrations of recombinant tau exogenously added to QC plasma samples were recovered
306 with 86-96% accuracy.

307 Additionally, the assay demonstrated selectivity to recombinant 2N4R tau441 vs. big tau
308 when titrated in buffer or in pooled plasma. The signals of samples spiked with various
309 concentrations of recombinant peripheral-tau did not differ from the non-spiked samples, both of
310 which were significantly lower than the corresponding signals for the 2N4R tau441 isoform
311 which increased proportionally to the spike level.

312 Our sample stability results showed that as the number of freeze/thaw cycles increases,
313 the levels of plasma BD-tau tend to increase, with significant increases at 6 and 8 f/t cycles.
314 This may be due to the disruption of protein complexes that lead to denaturation and release of
315 free peptides. For storage temperature, our results show that storing samples at room
316 temperature, 4°C, and -20°C for various periods of time does not significantly impact the levels
317 of plasma BD-tau in any manner.

318 We also tested correlations of BD-tau levels in different matrices. Plasma-serum and
319 CSF-plasma BD-tau pairs demonstrated strong correlations, indicating reliability independent of
320 matrix choice in alignment with findings from previous studies [6,18,19]. Yet, the absolute
321 concentrations in serum were significantly higher than those in paired plasma samples, which
322 contradicts previous findings from an initial assay prototype [18]. In the TBI cohort, group
323 differences in CSF and plasma were similar, meaning either matrix can be used but should be
324 used independently in a whole study.

325 It is noteworthy that, despite being within the error-allowable margin for the tested QC
326 samples, an unexplained apparent drift in signal was evident when the same samples were
327 measured in wells at the start vs. at the end of the same plate in an identical run. This drift was
328 observed when classifying assay signals using either AEBs values or estimated concentrations,
329 indicating that this issue cannot be explained by potential standard curve signal differences
330 between plates. Furthermore, our sample stability results showed that sample storage
331 temperature (4°C or RT) did not impact BD-tau readings. Thus, such drift could not be due to
332 temperature fluctuations between/during samples preparation and measurement. Additionally,
333 consistency of the observation across different Simoa HD-X instruments rules out an
334 instrument-related problem. Finally, paired t-testing on the number of beads for the same QC
335 samples from the start and end of plates did not reveal statistical differences ($p=0.1217$),
336 indicating the drift is likely not attributable to a difference in the amount of capture antibody.

337 We extended our analytical validation to clinical validation, examining a pilot TBI cohort.
338 Our results demonstrated the utility of BD-tau in distinguishing individuals with severe traumatic
339 brain injury at four days post-injury from those with chronic TBI, with only plasma BD-tau
340 distinguishing severely injured patients from controls. This may be due to the small sample
341 sizes in CSF groups. Moreover, plasma and CSF BD-tau were correlated, in agreement with
342 previous findings [6,19,22]. Since BD-tau separated outcome scores of those with chronic from
343 severe acute brain trauma in both plasma and CSF, BD-tau readings could facilitate predicting
344 unfavorable outcome and overall clinical management in the acute stages of traumatic brain
345 injury.

346 The correlation between plasma BD-tau with NfL and GFAP supports findings in other
347 studies that BD-tau elevation in TBI can be an indicator of neurodegeneration/neuronal injury
348 including in response to various processes including microglia activation [6,18,19,21,29]. A
349 contradictory finding with the literature is the lack of CSF BD-tau correlation with NfL and GFAP
350 for cmTBI or sTBI [22], perhaps due to the small CSF sample sizes, since they correlate in the
351 full cohort. Perhaps the most intriguing correlation revealed in this study is the significant
352 correlation between plasma BD-tau and p-tau217 across the full cohort and the sTBI and control
353 sub-groups. P-tau217 is one of the most effective predictors of AD and related cognitive decline
354 [7,30,31]. Larger cohorts are needed to verify these results. Another possibility is combining
355 these biomarker measurements to help determine whether underlying neurodegeneration is due
356 to AD when evaluating neurodegenerative diseases [7,21,30–32].

357 **Limitations**

358 Although comprehensive, our study has limitations including our preliminary TBI cohort
359 was relatively small and contained small within-diagnostic group numbers. In addition, the CSF
360 samples were limited, precluding a direct comparison of findings in paired CSF and plasma
361 samples from the same individuals.

362 **Conclusions**

363 In summary, our study provides independent evidence that the plasma BD-tau assay kit
364 has acceptable analytical performance as well as utility for evaluation of clinical TBI. Our
365 findings have multiple future implications, including providing the basis for establishing
366 guidelines for shipping and storage of plasma samples intended to test BD-tau levels. In
367 addition to analytical findings, our results show that plasma BD-tau levels distinguish between
368 severe TBI and chronic-mixed TBI, the former of which is associated with worse clinical
369 outcomes as indicated by GOS-E scores. Thus, our results indicate that immediate BD-tau
370 readings post-injury may provide an insight into the outcome and therefore allow for the
371 formulation of an appropriate treatment plan.

372 Abbreviations: CTE: Chronic traumatic encephalopathy; CV: Coefficient of variation; CVr:
373 Repeatability coefficient of variation; CVRw: Intermediate precision coefficient of variation;
374 (U/L)LOQ: (Upper/Lower) limit of quantification; 4-PL: Four-parameter logistic regression; AD:
375 Alzheimer's Disease; AD8: Ascertain Demential 8 item Questionnaire ; ADRC: Alzheimer's
376 Disease Research Center; AEB: Average enzyme per bead; APOE: Apolipoprotein E; Aß:
377 Amyloid beta; BD-tau Adv PLUS: BD-tau Advantage PLUS Kit; BD-tau: Brain-derived tau;
378 cmTBI: Chronic-mixed TBI; CNS: Central nervous syste; CSF: Cerebrospinal fluid; CT:
379 computed tomography; EDTA: ethylenediaminetetraacetic acid ; F/T: freeze/thaw; FDA: Food
380 and Drug Administration; GCS: Glasgow Coma Scale; GFAP: Glial-fibrillary acidic protein; GOS-
381 E: Glasgow Outcome Scale - Extended Version; HD-X: Quanterix®'s trademark name for their
382 instrument; NfL: neurofilament light chain; p-tau: phosphorylated tau; QC: Quality control;
383 Simoa: Single-molecule array; sTBI: Severe-acute TBI; TBI: Traumatic brain injury; t-tau: Total
384 tau; UCH-L1: Ubiquitin C-terminal hydrolase-L1.

385 Human Genes: *APOE:* Apolipoprotein E

Declarations

Ethics approval and consent to participate:

All patient samples were obtained with full written informed consent and approved by the University of Pittsburgh Institutional Review Board (ADRC study: MOD19110245-023; BTRC study: 19030228; Military CTE study: 19110161)

Consent for publication:

Not applicable.

Availability of data and materials

De-identified data generated in this study can be shared with qualified and identifiable investigators for the purpose of replicating the results and procedures in the study. Requests can be made to the corresponding author of the present study (T.K.K.) who will refer them to the respective cohort principal investigators where necessary. Requests will be reviewed by the investigators and respective institutions to ensure that each data request and transfer are in agreement with US legislation on general data protection or is subject to any intellectual property or confidentiality obligations. The purpose of these procedures is to ensure participant anonymity and ensure data safeguarding limited to the terms set forth in the IRB approvals. Data request can be made directly at https://www.adrc.pitt.edu/for-researchers/adrc-data-resources/ for Pittsburgh ADRC.

Competing interests

Thomas K. Karikari: TKK has consulted for Quanterix Corporation, SpearBio Inc., Neurogen Biomarking LLC., and Alzheon, has served on advisory boards for Siemens Healthineers and Neurogen Biomarking LLC., outside the submitted work. He has received in-kind research support from Janssen Research Laboratories, SpearBio Inc., and Alamar Biosciences, as well

409 as meeting travel support from the Alzheimer's Association and Neurogen Biomarking LLC.,
410 outside the submitted work. TKK has received royalties from Bioventix for the transfer of specific
411 antibodies and assays to third party organizations. He has received honoraria for speaker/grant
412 review engagements from the NIH, UPENN, UW-Madison, the Cherry Blossom symposium, the
413 HABS-HD/ADNI4 Health Enhancement Scientific Program, Advent Health Translational
414 Research Institute, Brain Health conference, Barcelona-Pittsburgh conference, the International
415 Neuropsychological Society, the Icahn School of Medicine at Mount Sinai and the Quebec
416 Center for Drug Discovery, Canada, all outside of the submitted work. TKK is an inventor on
417 several patents and provisional patents regarding biofluid biomarker methods, targets and
418 reagents/compositions, that may generate income for the institution and/or self should they be
419 licensed and/or transferred to another organization. These include WO2020193500A1: Use of a
420 ps396 assay to diagnose tauopathies; US 63/679,361: Methods to Evaluate Early-Stage Pre-
421 Tangle TAU Aggregates and Treatment of Alzheimer's Disease Patients; US 63/672,952:
422 Method for the Quantification of Plasma Amyloid-Beta Biomarkers in Alzheimer's Disease; US
423 63/693,956: Anti-tau Protein Antigen Binding Reagents; and 2450702-2: Detection of oligomeric
424 tau and soluble tau aggregates.

425 Funding:

426 TKK and the Karikari Laboratory members were supported by NIH/NIA (R01 AG083874,
427 U24AG082930, P30 AG066468, RF1 AG077474, R01 AG083156, R37 AG023651, R01
428 AG025516, R01 AG073267, R01 AG075336, R01 AG072641, P01 AG025204), NIH/NINDS (U01
429 NS131740, U01 NS141777), NIH/NIMH (R01 MH108509), Aging Mind Foundation
430 (DAF2255207), DoD (HT94252320064), the Anbridge Charitable Fund, and a professorial
431 endowment from the Department of Psychiatry, University of Pittsburgh. The content of this article
432 is solely the responsibility of the authors and does not necessarily represent the official views of
433 the funders.

434 Authors' contributions:

435 TKK, MNN, and XZ contributed to the study's conception and design. MNN ran biochemical
436 assays on TBI and ADRC cohorts, performed data analysis and produced the figures. ADC,
437 AMP, DOO, JKK, SES, OLL, XZ, and YC provided review and feedback on manuscript contents.
438 YC provided plasma/serum ADRC samples used in matrix comparisons. AMP, DOO, and SES
439 provided samples from TBI and BTRC cohort used in clinical validation. SES contributed to
440 writing the methods and provided participant information for the TBI and BTRC cohorts. All
441 authors contributed to and approved the final version of the manuscript.

442 Acknowledgements:

443 We express our appreciation to the Karikari Laboratory members, our collaborators at the Pitt-
444 ADRC and the Puccio Laboratory.

445

446

447

448

449

450

451

452

453

454

455

456 **References**

457 1. Lleó, A. Biomarkers in neurological disorders: a fast-growing market. *Brain Commun* **3**,
458 fcab086 (2021).
459 2. Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework.
460 *Clinical Pharmacology & Therapeutics* **69**, 89–95 (2001).
461 3. Lleó, A. *et al.* Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases.
462 *Nat Rev Neurol* **11**, 41–55 (2015).
463 4. Shoji, M. Cerebrospinal Fluid and Plasma Tau as a Biomarker for Brain Tauopathy. in *Tau*
464 *Biology* (eds Takashima, A., Wolozin, B. & Buee, L.) 393–405 (Springer, Singapore, 2019).
465 doi:10.1007/978-981-32-9358-8_29.
466 5. Hampel, H. & Blennow, K. CSF tau and β-amyloid as biomarkers for mild cognitive
467 impairment. *Dialogues Clin Neurosci* **6**, 379–390 (2004).
468 6. Gonzalez-Ortiz, F. *et al.* Brain-derived tau: a novel blood-based biomarker for Alzheimer's
469 disease-type neurodegeneration. *Brain* **146**, 1152–1165 (2023).
470 7. Telser, J., Risch, L., Saely, C. H., Grossmann, K. & Werner, P. P-tau217 in Alzheimer's
471 disease. *Clinica Chimica Acta* **531**, 100–111 (2022).
472 8. Blennow, K., Hampel, H., Weiner, M. & Zetterberg, H. Cerebrospinal fluid and plasma
473 biomarkers in Alzheimer disease. *Nat Rev Neurol* **6**, 131–144 (2010).
474 9. Brum, W. S. *et al.* Biological variation estimates of Alzheimer's disease plasma biomarkers
475 in healthy individuals. *Alzheimer's & Dementia* **20**, 1284–1297 (2024).
476 10. Noda, K., Lim, Y., Goto, R., Sengoku, S. & Kodama, K. Cost-effectiveness comparison
477 between blood biomarkers and conventional tests in Alzheimer's disease diagnosis. *Drug*
478 *Discovery Today* **29**, 103911 (2024).

11. Krawczuk, D., Kulczyńska-Przybik, A. & Mroczko, B. Clinical Application of Blood Biomarkers in Neurodegenerative Diseases—Present and Future Perspectives. *Int J Mol Sci* **25**, 8132 (2024).
12. Hardy-Sosa, A. *et al.* Diagnostic Accuracy of Blood-Based Biomarker Panels: A Systematic Review. *Front Aging Neurosci* **14**, 683689 (2022).
13. Shi, M., Chu, F., Zhu, F. & Zhu, J. Peripheral blood amyloid-β involved in the pathogenesis of Alzheimer's disease via impacting on peripheral innate immune cells. *Journal of Neuroinflammation* **21**, 5 (2024).
14. Xu, B. *et al.* Peripheral proteinopathy in neurodegenerative diseases. *Transl Neurodegener* **14**, 2 (2025).
15. Dugger, B. N. *et al.* The Presence of Select Tau Species in Human Peripheral Tissues and Their Relation to Alzheimer's Disease. *Journal of Alzheimer's Disease* **51**, 345–356 (2016).
16. Balczon, R. *et al.* Lung endothelium, tau, and amyloids in health and disease. *Physiological Reviews* **104**, 533–587 (2024).
17. Zetterberg, H. *et al.* Plasma tau levels in Alzheimer's disease. *Alzheimer's Research & Therapy* **5**, 9 (2013).
18. Gonzalez-Ortiz, F. *et al.* Preanalytical stability of plasma/serum brain-derived tau. *Alzheimer's & Dementia* **19**, 4764–4770 (2023).
19. Gonzalez-Ortiz, F. *et al.* Plasma brain-derived tau is an amyloid-associated neurodegeneration biomarker in Alzheimer's disease. *Nat Commun* **15**, 2908 (2024).
20. Clemmensen, F. K. *et al.* The plasma p-tau217/BD-tau ratio improves biomarker short-term variability in memory clinic patients. *Alzheimer's & Dementia: Translational Research & Clinical Interventions* **11**, e70143 (2025).
21. Gonzalez-Ortiz, F. *et al.* Levels of plasma brain-derived tau and p-tau181 in Alzheimer's disease and rapidly progressive dementias. *Alzheimer's & Dementia* **20**, 745–751 (2024).

504 22. Gonzalez-Ortiz, F. *et al.* Association of Serum Brain-Derived Tau With Clinical Outcome and
505 Longitudinal Change in Patients With Severe Traumatic Brain Injury. *JAMA Network Open* **6**,
506 e2321554 (2023).
507 23. Research, C. for D. E. and. Bioanalytical Method Validation Guidance for Industry.
508 https://www.fda.gov/regulatory-information/search-fda-guidance-documents/bioanalytical-
509 method-validation-guidance-industry (2020).
510 24. Andreasson, U. *et al.* A Practical Guide to Immunoassay Method Validation. *Front Neurol* **6**,
511 179 (2015).
512 25. Chen, Y. *et al.* Equivalence of plasma and serum for clinical measurement of p-tau217:
513 comparative analyses of four blood-based assays. *medRxiv* 2024.12.26.24319657 (2024)
514 doi:10.1101/2024.12.26.24319657.
515 26. Zeng, X. *et al.* Alzheimer blood biomarkers: practical guidelines for study design, sample
516 collection, processing, biobanking, measurement and result reporting. *Molecular*
517 *Neurodegeneration* **19**, 40 (2024).
518 27. BD-Tau Assay Kit -- Quanterix. *Quanterix* https://www.quanterix.com/simoa-assay-kits/bd-
519 tau/ (2024).
520 28. Gundersen, J. K. *et al.* Neuronal plasma biomarkers in acute ischemic stroke. *J Cereb*
521 *Blood Flow Metab* **45**, 77–84 (2025).
522 29. Leipp, F. *et al.* Glial fibrillary acidic protein in Alzheimer's disease: a narrative review. *Brain*
523 *Communications* **6**, fcae396 (2024).
524 30. Palmqvist, S. *et al.* Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer
525 Disease vs Other Neurodegenerative Disorders. *JAMA* **324**, 772 (2020).
526 31. Mattsson-Carlgren, N. *et al.* Prediction of Longitudinal Cognitive Decline in Preclinical
527 Alzheimer Disease Using Plasma Biomarkers. *JAMA Neurol* **80**, 360–369 (2023).

32. Asken, B. M. *et al.* Plasma P-tau181 and P-tau217 in Patients With Traumatic Encephalopathy Syndrome With and Without Evidence of Alzheimer Disease Pathology. *Neurology* **99**, e594–e604 (2022).

548 Figure legends

549 **Figure 1. Robustness and precision of plasma BD-tau.**

550 (A) Plot showing pooled data across 10 independent runs for three different pre-made QC
551 samples. Each sample was measured in duplicates at the start and at the end of the plate. The
552 mean values at the start (solid) vs. the end (hollow) for readings from the same plate are shown.
553 (B) Plot of the overall average readings for each QC per plate (combining the duplicate readings
554 at the start and at the end). (C) Normalized plasma BD-tau concentrations for the five samples
555 evaluated in the precision experiments. Single-use aliquots of each specimen were measured 25
556 individual times, across five runs over five different days. For each sample, the black dots show
557 the individual concentrations in a single precision run, the bars show the median, and error bars
558 show the inter-quartile range (IQR). (D) Measured (without normalization) sample concentrations
559 in the precision experiments.

560 **Figure 2. BD-tau assay specificity.**

561 Comparison of BD-tau assay readings when measured in equal concentrations of recombinant
562 forms of 2N4R CNS-abundant tau441 and the peripherally-enriched big tau isoform. The test
563 proteins were evaluated in two separate experimental conditions involving three theoretical
564 concentrations of the recombinant protein and the non-spiked matrix for background signal: (1)
565 dilution in the calibrator diluent following the manufacturer recommendations, and (2) four-fold
566 dilution in QC plasma to account for potential matrix effects.

567

568 **Figure 3. Dilution linearity of plasma BD-tau.**

569 A) Portrayal of dilution linearity of plasma samples showing the concentration from non-diluted
570 (ND) up to 4096-fold diluted, across four-fold stepwise decreases. B) The dilution-adjusted

571 relative errors at 4- and 16-fold dilutions for samples showing the adjustment which produced
572 concentration within ±20% the normalized concentration of the dilution-free (neat) sample
573 (shown as dotted red lines at 80% and 120%). Dilutions beyond 16-fold are not shown since
574 their normalized concentration exceeded 140%.

575

576 **Figure 4. Spike recovery of plasma BD-tau.**

577 Spike recovery in two four-fold diluted plasma samples at four different spike levels. The bars
578 indicate the percentage recovery in each sample at the given spike level, and the red dotted
579 lines at 80% and 120% show the acceptable range of recovery as described by field experts
580 *[24]*.

581

582 **Figure 5. Comparison of BD-tau levels in paired plasma vs. serum samples.**

583 (A) Comparison of the absolute concentrations of BD-tau in paired plasma/serum samples from
584 the University of Pittsburgh ADRC (n=48 viable pairs from a cohort of n=50). (B) Spearman
585 correlation between plasma and serum BD-tau concentrations. Each point represents a
586 plasma/serum pair, shown in red is the linear regression line.

587

588 **Figure 6. Clinical validation of plasma and CSF BD-tau in the pilot TBI cohort.**

589 BD-tau readings for control, chronic-mixed TBI (cmTBI), and severe-acute TBI (sTBI)
590 participants from a pilot cohort in both CSF (A) and plasma (B), plotted on a log(10) scale. All
591 data points are shown. Kruskal-Wallis multiple comparisons tests are shown comparing group
592 BD-tau distributions where significant differences are seen.


A
Within-Plate Robustness
Plasma BD-tau (pg/mL)
Plate
QCG
QCL
QCN30
B
Between-Plate Robustness
Plasma BD-tau (pg/mL)
Plate
QCG
QCL
QCN30
C
Precision - Normalized
Normalized Plasma BD-tau (%)
Day
Sample 1
Sample 2
Sample 3
Sample 4
Sample 5
D
Endogenous Sample Concentrations
Plasma BD-tau (pg/mL)
Sample 1
Sample 2
Sample 3
Sample 4
Sample 5


Specificity
BD-tau
Big-tau
BD-tau (pg/mL)
330
270
210
150
90
30
3
2
1
0
0
25
50
100
0
25
50
100
Assay buffer
QC plasma
Recombinant Protein Concentration (pg/mL)


A
Measured Concentration (Pre-Dilution Correction)
Plasma BD-tau (pg/mL)
400
300
200
100
0
Fold dilution
ND
4
16
64
256
1024
4096
Sample 1
Sample 2
Sample 3


B
Dilution-Adjusted Concentration
Normalized Concentration (%)
140
120
100
80
60
40
20
0
0
4
16
Fold Dilution
Sample 1
Sample 2
Sample 3


Spike Recovery
120
100
80
60
40
20
0
%Recovery
Spike
24 pg/mL
48 pg/mL
96 pg/mL
192 pg/mL
24 pg/mL
48 pg/mL
96 pg/mL
192 pg/mL
Sample 1
Sample 2


A
Plasma vs Serum
0.0001
BD-tau concentration (pg/mL)
50
40
30
20
10
0
Plasma
Serum
B
Plasma vs Serum
r = 0.8392
p<0.0001
Serum BD-tau (pg/mL)
50
40
30
20
10
0
0
5
10
15
20
25
Plasma BD-tau (pg/mL)


A
0.0286
100000
10000
1000
100
10
1
log CSF BD-tau (pg/mL)
Control
cmTBI
sTBI
CSF
B
<0.0001
<0.0001
1000
100
10
1
log Plasma BD-tau (pg/mL)
Control
cmTBI
sTBI
Plasma